Novartis back on track for growth in third quarter

Novartis reported Q3 revenue of $14.5B, up 4% YoY. Operating profit fell 59% to $1.8B due to a $1.9B write-down. Core operating profit rose to $6B, beating estimates. The company revised its full-year profit guidance to stable or slightly higher. According to the company, revenue growth is expected to remain in the low single-digit range.

Original reporting
Published Oct 27, 2026, 7:35 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 8:25 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Novartis back on track for growth in third quarter — source image
Decision brief

The 30-second read

$NVSBearishHigh
01

Why it matters

The earnings miss may trigger short‑term sell‑offs, though the company’s long‑term pipeline could mitigate the impact.

02

Market read

First‑report earnings release for a large‑cap pharma, providing actionable trading insight.

03

What to watch

Potential upside from AI‑driven drug discovery initiatives not reflected in the short‑term numbers.

Relevance 8/10Novelty 8/10Timing: post-market today

Background

Novartis disclosed its Q3 results, highlighting modest revenue growth but a sharp profit decline due to a $1.9B write‑down.

Company-level read

Ticker impact

$NVSBearishHigh confidence
Context

Novartis reported Q3 revenue of $14.5B and a 59% drop in operating profit, revising full-year profit guidance.

Expected impact

likely downward pressure as investors price in lower profit and modest revenue growth

Evidence & confidence

The sizable profit decline and guidance revision are fresh, material information for a large-cap pharma.

Market effects

May dampen sentiment for the broader pharma sector as peers face similar generic erosion.

European markets could see slight weakness in healthcare indices.

Limited to pharma; not a macro driver.

Counterpoint

If the revenue growth holds and generic erosion peaks, the stock could rebound on longer‑term outlook.

Key entities

  • Novartis

    Swiss‑based pharmaceutical giant (ticker NVS).

Related articles

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$NVSMedAI 8/10

Novartis Trims Growth Target at Annual Management Day, Shares Slide

Novartis reduced its mid-term sales growth outlook to 5% annually from 2026-2031, down from a prior 5-6% range. Shares fell 3% on the news. The revision follows patent expirations and clinical trial failures, including a $2.2B writedown. Despite this, Novartis raised peak sales forecasts for three key drugs: Kesimpta, Scemblix, and Leqvio. The company expects growth beyond 2031 from internally developed medicines, with 10 in late-stage development.

$NVSMed

Novartis trims medium-term growth target, shares fall

Novartis reduced its annual sales growth target to 5% through 2031, down from a previous range of 5%-6%. Shares fell 3.3% after the announcement, which came amid patent expirations and clinical trial setbacks. The company expects growth from existing drugs like Kesimpta, Scemblix, and Leqvio, with no large acquisitions planned. Analysts anticipate growth slowing post-2030 due to competition for key drugs.